Following Veniti Inc.'s completion of a PMA application for its Vici venous stent system, Boston Scientific Corp. has agreed to pay $108m upfront, plus $52m in milestones, to acquire the 75% of Veniti that it does not already own, the companies announced Aug. 8.
Boston Scientific first invested in Veniti in 2016 and currently owns 25% of the Fremont, Calif.-based private company. The $52m milestone is contingent on US FDA approval of Vici for...